Yuee Teng

机构：Yantai University, Yuhuangding Hospital, Nanjing Maternity and Child Health Care Hospital, Nanjing Medical University · ORCID：0009-0000-3759-6707

发表论文 37 篇 · 总被引 360 次 · h-index 10

代表论文

• Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial (2025 · Nature Medicine · 被引 53)
• Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study. (2024 · Journal of Clinical Oncology · 被引 47)
• Molecular subtypes predict the preferential site of distant metastasis in advanced breast cancer: a nationwide retrospective study (2023 · Frontiers in Oncology · 被引 31)
• Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort (2025 · Nature Communications · 被引 15)
• Abstract CT175: Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing/mutated advanced solid tumors: A global phase 1, multi-center, first-in-human study (2023 · Cancer Research · 被引 13)
• Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study. (2025 · Journal of Clinical Oncology · 被引 11)